middle.news
How Acrux’s $3.04M R&D Rebate Could Accelerate Its Pharma Pipeline
8:33am on Thursday 4th of September, 2025 AEST
•
Healthcare
Read Story
How Acrux’s $3.04M R&D Rebate Could Accelerate Its Pharma Pipeline
8:33am on Thursday 4th of September, 2025 AEST
Key Points
Received $3.04 million R&D Tax Incentive rebate for FY25
Fully repaid short-term funding facility from Radium Capital
Rebate reflects ongoing investment in Australian R&D
Supports Acrux’s specialty pharmaceutical development pipeline
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Acrux (ASX:ACR)
OPEN ARTICLE